Autopsy report · NCT00928200
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Cause of deathSlow enrollment
“Study was terminated due to lack of accrual.”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 1 year 2 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 8 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Sponsor type
- University, hospital or other
- Conditions
- Relapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli Asparaginase
- Interventions
- Erwinase; Vincristine; Dexamethasone; Doxorubicin; Cytarabine; Methotrexate
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
“Study has been terminated due to poor accrual.” - Pembrolizumab + Idelalisib for Lung Cancer Study
“The study was terminated due to poor accrual.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.” - Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
“Study was terminated due to poor accrual” - Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
“The study was terminated due to low accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.